NCT06348134View on ClinicalTrials.gov

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

July 1, 2034

Study Completion Date

July 1, 2036

Conditions
Human Epidermal Growth Factor 2 Negative Carcinoma of BreastHER2-positive Breast CancerBreast Cancer
Interventions
DRUG

Trastuzumab emtansine

A chemotherapy drug.

DRUG

Pertuzumab Injection

A prescription medicine that is approved for use in combination with trastuzumab and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.

DRUG

Docetaxel

A chemotherapy drug.

DRUG

Tamoxifen

A medication used to treat breast cancer.

DRUG

Letrozole

A medication used to treat breast cancer.

DRUG

Goserelin

A hormone therapy drug.

Trial Locations (5)

60615

University of Chicago, Chicago

100254

Lagos University Teaching Hospital, Yaba

100271

Lagos State University Teaching Hospital, Ikeja

200285

University of Ibadan Hospital, Ibadan

220005

Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC), Ile-Ife

All Listed Sponsors
lead

University of Chicago

OTHER